Taizhen Liang, Shiqi Xiao, Ziyao Wu, Xi Lv, Sen Liu, Meilin Hu, Guojie Li, Peiwen Li, Xiancai Ma
Viruses 2023 Jul 31Novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and continues to threaten humanity due to the persistent emergence of new variants. Therefore, developing more effective and broad-spectrum therapeutic and prophylactic drugs against infection by SARS-CoV-2 and its variants, as well as future emerging CoVs, is urgently needed. In this study, we screened several US FDA-approved drugs and identified phenothiazine derivatives with the ability to potently inhibit the infection of pseudotyped SARS-CoV-2 and distinct variants of concern (VOCs), including B.1.617.2 (Delta) and currently circulating Omicron sublineages XBB and BQ.1.1, as well as pseudotyped SARS-CoV and MERS-CoV. Mechanistic studies suggested that phenothiazines predominantly inhibited SARS-CoV-2 pseudovirus (PsV) infection at the early stage and potentially bound to the spike (S) protein of SARS-CoV-2, which may prevent the proteolytic cleavage of the S protein, thereby exhibiting inhibitory activity against SARS-CoV-2 infection. In summary, our findings suggest that phenothiazines can serve as a potential broad-spectrum therapeutic drug for the treatment of SARS-CoV-2 infection as well as the infection of future emerging human coronaviruses (HCoVs).
Taizhen Liang, Shiqi Xiao, Ziyao Wu, Xi Lv, Sen Liu, Meilin Hu, Guojie Li, Peiwen Li, Xiancai Ma. Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein. Viruses. 2023 Jul 31;15(8)
PMID: 37632009
View Full Text